[{"id":"089a9873-0dbf-4d04-a926-ae092495901f","acronym":"ComboMATCH","url":"https://clinicaltrials.gov/study/NCT05554380","created_at":"2022-09-26T14:56:10.419Z","updated_at":"2025-02-25T12:38:22.753Z","phase":"Phase 2","brief_title":"Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial","source_id_and_acronym":"NCT05554380 - ComboMATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" AKT2","pipe":" | ","alterations":" AKT1 mutation","tags":["AKT2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AKT1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • ipatasertib (RG7440)"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 09/22/2023","start_date":" 09/22/2023","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 08/31/2025","study_completion_date":" 08/31/2025","last_update_posted":"2025-02-24"},{"id":"0cab49cd-f269-4139-a170-355e5106eb01","acronym":"","url":"https://clinicaltrials.gov/study/NCT05564377","created_at":"2022-10-03T15:56:45.241Z","updated_at":"2025-02-25T12:29:02.892Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial","source_id_and_acronym":"NCT05564377","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Ibrance (palbociclib) • paclitaxel • Vectibix (panitumumab) • Koselugo (selumetinib) • Nerlynx (neratinib) • Piqray (alpelisib) • Lumakras (sotorasib) • Mektovi (binimetinib) • nilotinib • fulvestrant • oxaliplatin • ipatasertib (RG7440) • leucovorin calcium • fluorouracil topical"],"overall_status":"Recruiting","enrollment":" Enrollment 2900","initiation":"Initiation: 04/07/2023","start_date":" 04/07/2023","primary_txt":" Primary completion: 07/01/2030","primary_completion_date":" 07/01/2030","study_txt":" Completion: 07/01/2030","study_completion_date":" 07/01/2030","last_update_posted":"2025-02-24"},{"id":"15959a9a-70ff-446f-ba15-1dcc1140abaf","acronym":"NRG-GY028","url":"https://clinicaltrials.gov/study/NCT05538897","created_at":"2022-09-14T18:56:09.184Z","updated_at":"2025-02-25T13:49:32.512Z","phase":"Phase 1/2","brief_title":"Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers","source_id_and_acronym":"NCT05538897 - NRG-GY028","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" AKT1S1","pipe":"","alterations":" ","tags":["AKT1S1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ipatasertib (RG7440) • megestrol"],"overall_status":"Recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 03/31/2023","start_date":" 03/31/2023","primary_txt":" Primary completion: 01/31/2027","primary_completion_date":" 01/31/2027","study_txt":" Completion: 01/31/2027","study_completion_date":" 01/31/2027","last_update_posted":"2025-02-20"},{"id":"ce9dfb12-840f-46f6-b8d1-947639822665","acronym":"Morpheus Lung","url":"https://clinicaltrials.gov/study/NCT03337698","created_at":"2021-01-18T16:29:17.212Z","updated_at":"2025-02-25T13:48:26.615Z","phase":"Phase 1/2","brief_title":"A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)","source_id_and_acronym":"NCT03337698 - Morpheus Lung","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • gemcitabine • docetaxel • Cotellic (cobimetinib) • pemetrexed • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • Repatha (evolocumab) • camonsertib (RP-3500) • cibisatamab (RG7802) • ciforadenant (CPI-444) • zanzalintinib (XL092)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 314","initiation":"Initiation: 12/27/2017","start_date":" 12/27/2017","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2025-02-20"},{"id":"137ec32f-5e52-4616-9b33-b322d2b339d9","acronym":"TAPISTRY","url":"https://clinicaltrials.gov/study/NCT04589845","created_at":"2021-04-08T16:52:35.237Z","updated_at":"2025-02-25T14:07:57.580Z","phase":"Phase 2","brief_title":"Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study","source_id_and_acronym":"NCT04589845 - TAPISTRY","lead_sponsor":"Hoffmann-La Roche","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Rozlytrek (entrectinib) • Alecensa (alectinib) • Kadcyla (ado-trastuzumab emtansine) • Gavreto (pralsetinib) • ipatasertib (RG7440) • belvarafenib (RG6185) • idasanutlin (RG7388) • divarasib (RG6330) • Itovebi (inavolisib) • camonsertib (RP-3500)"],"overall_status":"Recruiting","enrollment":" Enrollment 920","initiation":"Initiation: 01/18/2021","start_date":" 01/18/2021","primary_txt":" Primary completion: 09/25/2032","primary_completion_date":" 09/25/2032","study_txt":" Completion: 09/25/2032","study_completion_date":" 09/25/2032","last_update_posted":"2025-02-17"},{"id":"d5e3296e-7887-47f7-a8e8-e85cdb5b5e2b","acronym":"MORPHEUS BC","url":"https://clinicaltrials.gov/study/NCT04802759","created_at":"2021-03-17T15:57:40.908Z","updated_at":"2025-02-25T12:28:00.493Z","phase":"Phase 1/2","brief_title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer","source_id_and_acronym":"NCT04802759 - MORPHEUS BC","lead_sponsor":"Hoffmann-La Roche","biomarkers":" ER • CDK4","pipe":" | ","alterations":" HER-2 positive • ER positive","tags":["ER • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • everolimus • Verzenio (abemaciclib) • Kisqali (ribociclib) • ipatasertib (RG7440) • Itovebi (inavolisib) • giredestrant (RG6171) • Pegasys (pegylated interferon α -2a) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • samuraciclib (CT7001)"],"overall_status":"Recruiting","enrollment":" Enrollment 316","initiation":"Initiation: 06/22/2021","start_date":" 06/22/2021","primary_txt":" Primary completion: 11/30/2027","primary_completion_date":" 11/30/2027","study_txt":" Completion: 11/30/2027","study_completion_date":" 11/30/2027","last_update_posted":"2025-02-17"},{"id":"f6a27acf-7978-4c4b-a907-56c547d54b2a","acronym":"Morpheus-TNBC","url":"https://clinicaltrials.gov/study/NCT03424005","created_at":"2021-01-18T16:53:25.262Z","updated_at":"2025-02-25T15:17:38.740Z","phase":"Phase 1/2","brief_title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","source_id_and_acronym":"NCT03424005 - Morpheus-TNBC","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • PD-L1 • PIK3CA","pipe":" | ","alterations":" PD-L1 expression • PIK3CA mutation","tags":["HER-2 • PD-L1 • PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • gemcitabine • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • Verzenio (abemaciclib) • albumin-bound paclitaxel • Kisqali (ribociclib) • fulvestrant • Halaven (eribulin mesylate) • letrozole • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • Itovebi (inavolisib) • Actemra IV (tocilizumab) • ladiratuzumab vedotin (SGN-LIV1A) • selicrelumab (RG7876)"],"overall_status":"Recruiting","enrollment":" Enrollment 580","initiation":"Initiation: 03/30/2018","start_date":" 03/30/2018","primary_txt":" Primary completion: 05/03/2028","primary_completion_date":" 05/03/2028","study_txt":" Completion: 05/03/2028","study_completion_date":" 05/03/2028","last_update_posted":"2025-02-10"},{"id":"696d727b-575b-4b42-9ab7-71058751cfe0","acronym":"NCI-2021-13902","url":"https://clinicaltrials.gov/study/NCT05172258","created_at":"2021-12-29T13:53:34.637Z","updated_at":"2025-02-25T16:32:39.281Z","phase":"Phase 2","brief_title":"Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck","source_id_and_acronym":"NCT05172258 - NCI-2021-13902","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • ipatasertib (RG7440) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 07/26/2022","start_date":" 07/26/2022","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-07"},{"id":"d42429d0-899b-4f9f-a9fd-c90fa6b9a50e","acronym":"NRG-GY027","url":"https://clinicaltrials.gov/study/NCT05276973","created_at":"2022-03-14T14:54:04.422Z","updated_at":"2025-02-25T16:38:53.900Z","phase":"Phase 1","brief_title":"Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer","source_id_and_acronym":"NCT05276973 - NRG-GY027","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PTEN • HRD • NF1 • AKT1 • TSC1 • AKT1S1","pipe":" | ","alterations":" HRD","tags":["PTEN • HRD • NF1 • AKT1 • TSC1 • AKT1S1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • ipatasertib (RG7440)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 09/08/2022","start_date":" 09/08/2022","primary_txt":" Primary completion: 01/30/2025","primary_completion_date":" 01/30/2025","study_txt":" Completion: 01/30/2025","study_completion_date":" 01/30/2025","last_update_posted":"2025-02-07"},{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"75f0b64e-2f38-4d3f-986a-4f0367fd8684","acronym":"BOUQUET","url":"https://clinicaltrials.gov/study/NCT04931342","created_at":"2022-05-03T17:53:37.321Z","updated_at":"2024-07-02T16:34:26.433Z","phase":"Phase 2","brief_title":"A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors","source_id_and_acronym":"NCT04931342 - BOUQUET","lead_sponsor":"Hoffmann-La Roche","biomarkers":" ER","pipe":"","alterations":" ","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Lynparza (olaparib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • paclitaxel • Kadcyla (ado-trastuzumab emtansine) • Cotellic (cobimetinib) • Verzenio (abemaciclib) • cyclophosphamide • letrozole • ipatasertib (RG7440) • triptorelin • goserelin acetate • Itovebi (inavolisib) • giredestrant (RG6171)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 176","initiation":"Initiation: 10/07/2021","start_date":" 10/07/2021","primary_txt":" Primary completion: 05/30/2028","primary_completion_date":" 05/30/2028","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2024-06-13"},{"id":"64151ea0-5e4f-4551-a71f-36af8cc5de9e","acronym":"IPATential150","url":"https://clinicaltrials.gov/study/NCT03072238","created_at":"2021-01-17T17:45:45.867Z","updated_at":"2024-07-02T16:34:37.052Z","phase":"Phase 3","brief_title":"Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer","source_id_and_acronym":"NCT03072238 - IPATential150","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PTEN","pipe":" | ","alterations":" PTEN loss","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN loss"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • ipatasertib (RG7440) • prednisone • prednisolone"],"overall_status":"Completed","enrollment":" Enrollment 1101","initiation":"Initiation: 06/30/2017","start_date":" 06/30/2017","primary_txt":" Primary completion: 03/16/2020","primary_completion_date":" 03/16/2020","study_txt":" Completion: 04/24/2024","study_completion_date":" 04/24/2024","last_update_posted":"2024-06-07"},{"id":"ded04c2b-2ead-4cff-9660-0481bc077bfe","acronym":"MORPHEUS","url":"https://clinicaltrials.gov/study/NCT03280563","created_at":"2021-01-18T16:11:59.285Z","updated_at":"2024-07-02T16:34:37.795Z","phase":"Phase 1/2","brief_title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer","source_id_and_acronym":"NCT03280563 - MORPHEUS","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • PD-L1","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive","tags":["HER-2 • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • tamoxifen • Verzenio (abemaciclib) • fulvestrant • ipatasertib (RG7440) • exemestane • Jingzhuda (entinostat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 138","initiation":"Initiation: 12/26/2017","start_date":" 12/26/2017","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-06-06"},{"id":"5a4a7ea1-f6f6-41ac-a252-4ee9ed1147d3","acronym":"FINER","url":"https://clinicaltrials.gov/study/NCT04650581","created_at":"2021-01-19T20:40:12.739Z","updated_at":"2024-07-02T16:35:04.541Z","phase":"Phase 3","brief_title":"Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor","source_id_and_acronym":"NCT04650581 - FINER","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • ipatasertib (RG7440)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 01/27/2021","start_date":" 01/27/2021","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-05-09"},{"id":"14763699-a9a1-4656-939a-4ccb4819119b","acronym":"BIS-Program","url":"https://clinicaltrials.gov/study/NCT05180006","created_at":"2022-01-06T23:53:44.740Z","updated_at":"2025-02-25T12:28:33.945Z","phase":"Phase 2","brief_title":"Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy","source_id_and_acronym":"NCT05180006 - BIS-Program","lead_sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","biomarkers":" HER-2 • PGR • GZMB","pipe":" | ","alterations":" HER-2 positive • HER-2 overexpression • HER-2 amplification • HER-2 positive + HER-2 overexpression","tags":["HER-2 • PGR • GZMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 overexpression • HER-2 amplification • HER-2 positive + HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Herceptin (trastuzumab) • Tecentriq (atezolizumab) • Perjeta (pertuzumab) • ipatasertib (RG7440)"],"overall_status":"Recruiting","enrollment":" Enrollment 185","initiation":"Initiation: 02/24/2022","start_date":" 02/24/2022","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-04-18"},{"id":"a2213fc9-71f6-45fe-999d-22872e7dff92","acronym":"TAKTIC","url":"https://clinicaltrials.gov/study/NCT03959891","created_at":"2021-01-18T19:29:12.762Z","updated_at":"2024-07-02T16:35:09.477Z","phase":"Phase 1","brief_title":"AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)","source_id_and_acronym":"NCT03959891 - TAKTIC","lead_sponsor":"Massachusetts General Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • fulvestrant • letrozole • ipatasertib (RG7440)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 77","initiation":"Initiation: 05/30/2019","start_date":" 05/30/2019","primary_txt":" Primary completion: 12/25/2022","primary_completion_date":" 12/25/2022","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-04-16"},{"id":"1a9d02fc-4481-4eea-ba56-e657f8739070","acronym":"IPATunity170","url":"https://clinicaltrials.gov/study/NCT04177108","created_at":"2021-01-18T20:22:20.817Z","updated_at":"2024-07-02T16:35:12.631Z","phase":"Phase 3","brief_title":"A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer","source_id_and_acronym":"NCT04177108 - IPATunity170","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • paclitaxel • ipatasertib (RG7440)"],"overall_status":"Completed","enrollment":" Enrollment 242","initiation":"Initiation: 11/25/2019","start_date":" 11/25/2019","primary_txt":" Primary completion: 02/28/2023","primary_completion_date":" 02/28/2023","study_txt":" Completion: 02/28/2023","study_completion_date":" 02/28/2023","last_update_posted":"2024-03-27"},{"id":"21a8be08-eefa-4035-aec2-4a3752975586","acronym":"IPATunity130","url":"https://clinicaltrials.gov/study/NCT03337724","created_at":"2021-01-17T17:26:41.567Z","updated_at":"2024-07-02T16:35:15.265Z","phase":"Phase 3","brief_title":"A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer","source_id_and_acronym":"NCT03337724 - IPATunity130","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • PIK3CA • PTEN • AKT1","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PIK3CA • PTEN • AKT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • ipatasertib (RG7440)"],"overall_status":"Completed","enrollment":" Enrollment 579","initiation":"Initiation: 01/06/2018","start_date":" 01/06/2018","primary_txt":" Primary completion: 01/04/2023","primary_completion_date":" 01/04/2023","study_txt":" Completion: 01/04/2023","study_completion_date":" 01/04/2023","last_update_posted":"2024-03-12"},{"id":"afc19c8b-1c15-4ecb-a7b5-c7d512137eb6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03853707","created_at":"2021-01-18T19:01:13.878Z","updated_at":"2024-07-02T16:35:18.974Z","phase":"Phase 1/2","brief_title":"Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer","source_id_and_acronym":"NCT03853707","lead_sponsor":"City of Hope Medical Center","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • carboplatin • paclitaxel • capecitabine • ipatasertib (RG7440)"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 03/04/2019","start_date":" 03/04/2019","primary_txt":" Primary completion: 01/21/2023","primary_completion_date":" 01/21/2023","study_txt":" Completion: 09/19/2023","study_completion_date":" 09/19/2023","last_update_posted":"2024-02-19"},{"id":"db496152-074a-4f24-8709-efd837f605cb","acronym":"ASPRIA","url":"https://clinicaltrials.gov/study/NCT04434040","created_at":"2021-01-18T21:21:04.269Z","updated_at":"2024-07-02T16:35:22.544Z","phase":"Phase 2","brief_title":"Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)","source_id_and_acronym":"NCT04434040 - ASPRIA","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • loperamide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 07/02/2020","start_date":" 07/02/2020","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2027","study_completion_date":" 12/30/2027","last_update_posted":"2024-01-23"},{"id":"f61f6186-aed3-4f85-9f8c-28c299c5550f","acronym":"PATHFINDER","url":"https://clinicaltrials.gov/study/NCT04464174","created_at":"2021-01-18T21:27:31.929Z","updated_at":"2024-07-02T16:35:29.196Z","phase":"Phase 2","brief_title":"Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer","source_id_and_acronym":"NCT04464174 - PATHFINDER","lead_sponsor":"MedSIR","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER expression","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • capecitabine • Halaven (eribulin mesylate) • ipatasertib (RG7440)"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 10/08/2020","start_date":" 10/08/2020","primary_txt":" Primary completion: 11/10/2023","primary_completion_date":" 11/10/2023","study_txt":" Completion: 11/10/2023","study_completion_date":" 11/10/2023","last_update_posted":"2023-11-15"},{"id":"b5f677ab-53f6-4549-8ee9-29923b7542ec","acronym":"","url":"https://clinicaltrials.gov/study/NCT03840200","created_at":"2021-01-18T18:57:28.084Z","updated_at":"2024-07-02T16:35:31.269Z","phase":"Phase 1","brief_title":"A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.","source_id_and_acronym":"NCT03840200","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • ER • MUC16","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • Rubraca (rucaparib) • abiraterone acetate • ipatasertib (RG7440)"],"overall_status":"Completed","enrollment":" Enrollment 51","initiation":"Initiation: 06/12/2019","start_date":" 06/12/2019","primary_txt":" Primary completion: 12/07/2021","primary_completion_date":" 12/07/2021","study_txt":" Completion: 01/04/2022","study_completion_date":" 01/04/2022","last_update_posted":"2023-10-30"},{"id":"68ced0d1-5116-4b3d-8079-1a15f3e6de8f","acronym":"FAIM","url":"https://clinicaltrials.gov/study/NCT04920708","created_at":"2021-06-11T00:54:37.032Z","updated_at":"2024-07-02T16:35:31.322Z","phase":"Phase 2","brief_title":"Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression","source_id_and_acronym":"NCT04920708 - FAIM","lead_sponsor":"Royal Marsden NHS Foundation Trust","biomarkers":" HER-2 • ER • PIK3CA • PTEN • AKT1","pipe":" | ","alterations":" HER-2 positive • ER positive • HER-2 negative • PIK3CA mutation • HER-2 mutation • ER positive + HER-2 negative • CDK4 mutation","tags":["HER-2 • ER • PIK3CA • PTEN • AKT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HER-2 negative • PIK3CA mutation • HER-2 mutation • ER positive + HER-2 negative • CDK4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • ipatasertib (RG7440) • Pegasys (pegylated interferon α -2a)"],"overall_status":"Recruiting","enrollment":" Enrollment 324","initiation":"Initiation: 12/28/2022","start_date":" 12/28/2022","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2023-10-27"},{"id":"14f82f5c-e429-4d17-9a3b-88bdc7d125c9","acronym":"ROME","url":"https://clinicaltrials.gov/study/NCT04591431","created_at":"2021-01-19T20:28:32.767Z","updated_at":"2025-02-25T13:53:27.554Z","phase":"Phase 2","brief_title":"The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy","source_id_and_acronym":"NCT04591431 - ROME","lead_sponsor":"Fondazione per la Medicina Personalizzata","biomarkers":" PD-L1 • BRAF","pipe":"","alterations":" ","tags":["PD-L1 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Tecentriq (atezolizumab) • erlotinib • Yervoy (ipilimumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Rozlytrek (entrectinib) • everolimus • lapatinib • Alecensa (alectinib) • Perjeta (pertuzumab) • Iclusig (ponatinib) • Kadcyla (ado-trastuzumab emtansine) • Cotellic (cobimetinib) • Talzenna (talazoparib) • Piqray (alpelisib) • Retevmo (selpercatinib) • Alunbrig (brigatinib) • Gavreto (pralsetinib) • Pemazyre (pemigatinib) • ipatasertib (RG7440) • Tepmetko (tepotinib) • itacitinib (INCB039110)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 10/07/2020","start_date":" 10/07/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-10-03"}]